Evolus (EOLS) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Revenue: $90.3 million, a 14% increase year-over-year.

Full Year 2025 Revenue: $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth.

Jeuveau Revenue: $83.1 million in Q4, contributing significantly to overall revenue.

Evolysse Revenue: $7.2 million in Q4, with over 3,000 accounts purchasing the product.

Gross Margin: Approximately 66% for both Q4 and full year 2025.

Operating Expenses: Q4 GAAP operating expenses were $55.1 million, down from $57.3 million in Q3. Full year 2025 GAAP operating expenses were $229.8 million, compared to $216.7 million in 2024.

Cash Position: Ended Q4 with $53.8 million in cash, up from $43.5 million in Q3.

2Strategic Updates and Business Highlights

Evolus is focusing on a "beauty first" strategy, emphasizing cash-pay aesthetics and building partnerships with aesthetic practices.

Launched the Evolux program, rewarding practices with co-branded media investment based on purchase volumes.

Evolus Rewards program has grown to over 1.4 million treated patients, enhancing brand loyalty.

Introduced Evolysse, a new HA technology, with positive clinician feedback and plans for a broader sampling program in 2026.

International revenue nearly doubled year-over-year, now representing about 8% of total revenue, with significant growth in markets like the U.K.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected between $327 million and $337 million, representing 10% to 13% growth over 2025.

Adjusted EBITDA Margin: Projected to be low to mid-single digits in 2026.

Anticipating FDA approval for Evolysse Sculpt in Q4 2026, which is expected to strengthen the product portfolio.

Targeting revenue of $450 million to $500 million by 2028, with adjusted EBITDA margins of 13% to 15%.

4Bad News, Challenges, or Points of Concern

The U.S. aesthetic market saw a decline in injectable procedural volumes for only the third time in 25 years, impacting overall market dynamics.

Evolus faces competitive pressures with new entrants expected in 2026, including AbbVie and Galderma, which may affect market share.

The filler market is still under pressure, and while there are signs of improvement, it is not expected to fully recover in the near term.

Tariffs on Evolysse could impact pricing and margins, with ongoing evaluations of potential recovery for previously paid tariffs.

5Notable Q&A Insights

Evolysse's growth is diversifying, with increasing adoption beyond early adopters, supported by a new portfolio growth rebate program.

There is optimism about the potential recovery of the filler market, although it is expected to remain under pressure in the short term.

The company is closely monitoring competitive launches and believes its differentiated product offerings will help maintain market share.

Clinicians are responding positively to Evolysse's unique formulation, which allows for more natural-looking results with less product.

The company is not planning to raise equity capital and is focused on maintaining a disciplined approach to capital allocation and expense management. Overall, Evolus demonstrated resilience in a challenging market, with a solid growth trajectory and strategic initiatives aimed at enhancing its competitive position in the aesthetics industry.